📰 BloombergBloombergDoubao · 实盘不做把握 8/10不做原因:标的无直接敞口
北京时间·🕒 发布 04:25:12·⟳ 抓取 04:30:55 +5m43s·⚡ 决策 09-15 04:32:29 +1m34s·42.8 天前
Tempus AI 创始人 Lefkofsky 公开支持 Anthropic CEO Amodei 关于放缓 AI 模型开发节奏的呼吁
这是一篇观点性人物访谈：Tempus AI CEO 对 AI 开发节奏表达个人态度，不含任何公司层面或可量化的行业供需/资本开支事实变化，对任何可交易标的都没有可建立因果链的增量信息，做多做空均无 edge。
📄 原文Bloomberg↗ 原文
The founder of Tempus AI Inc., a health technology company working with virtually all of the world’s major drugmakers,…
不做 Tempus AI Inc.（TEM.US）
报道仅为 CEO 对 AI 行业开发节奏的个人观点，无收入/客户/产品/指引等公司基本面增量，无可交易因果链；其余被提及方（Anthropic 未上市、AI 算力链）亦无实质敞口，不具多空 edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Tempus AI 创始人在 Bloomberg 访谈中附和 Anthropic 关于放缓 AI 的呼吁，纯属高管个人观点，无订单、业绩、指引或政策动作；对 Tempus 及 AI/算力链均无基本面增量，不构成可交易事件。
🔎 新鲜度:最早出现 2026-09-14 · 扩散 low · price-in 风险 low ↗
主要风险
- 若后续有具资本开支决策权的超大买家或监管机构跟进类似表态，可能转为对算力链的实质情绪扰动，但本条单一人物评论不构成该信号。
先例如何影响了这次决策
对本次决策的影响:缺乏可交易催化与先例，直接支持 AVOID，未生成任何仓位或价格条件。
方向:无可对照的高管泛论 AI 节奏类事件能稳定预测个股或板块方向；此类观点性访谈缺乏可量化锚点，不适合用先例校准幅度。
涨幅量级:无足以校准涨跌幅的高相似对齐先例，且事件本身无基本面增量，不据此设定止盈止损。
形态:无证据表明此类单一个人评论会带来可交易的方向性反应。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 62 ms
{"result": "search_processed_events:agent query=`tempus ai eric lefkofsky anthropic amodei slowdown ai development | tempus ai founder supports slowing ai model development bloomberg interview`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前
原文全文
展开原文 · 1,753 字
The founder of Tempus AI Inc., a health technology company working with virtually all of the world’s major drugmakers, threw his support behind Anthropic PBC’s Dario Amodei and his call for slowing the pace of artificial intelligence model development.
“I can imagine that, given the fact that the models now are training themselves and improving themselves, that there’s a point where you’re like, ‘Is this going to get beyond us?’” Tempus AI Chief Executive Officer Eric Lefkofsky said in an interview Monday at Bloomberg News headquarters in New York.
Lefkofsky, a co-founder of Groupon Inc., said he agreed with slowing down AI development both for security reasons and on capital efficiency grounds. He praised the work that Anthropic, OpenAI and SpaceX are doing in healthcare and downplayed concerns that the US may fall behind if its biggest players temper the pace of their investment.
“I don’t think there’s any real danger of if we if we go from driving 100 miles an hour, to driving 70 miles an hour,” Lefkofsky said. “I don’t think the rest of the world is going to overtake us.”
Lefkofsky founded Tempus AI in 2015, soon after his wife was diagnosed with breast cancer. The Chicago-based company has built one of the world’s largest libraries of clinical and molecular data. Tempus AI licenses that data to pharma companies to help them develop clinical trials and match patients with the right cancer drugs. It also has ambitions to expand in other areas, including cardiovascular disease.
Tempus AI shares have risen 68% since the company’s June 2024 initial public offering, giving the company an $11.2 billion market capitalization. It’s one of six companies that Lefkofsky, 57, started that’s been valued at more than $1 billion.
“I can imagine that, given the fact that the models now are training themselves and improving themselves, that there’s a point where you’re like, ‘Is this going to get beyond us?’” Tempus AI Chief Executive Officer Eric Lefkofsky said in an interview Monday at Bloomberg News headquarters in New York.
Lefkofsky, a co-founder of Groupon Inc., said he agreed with slowing down AI development both for security reasons and on capital efficiency grounds. He praised the work that Anthropic, OpenAI and SpaceX are doing in healthcare and downplayed concerns that the US may fall behind if its biggest players temper the pace of their investment.
“I don’t think there’s any real danger of if we if we go from driving 100 miles an hour, to driving 70 miles an hour,” Lefkofsky said. “I don’t think the rest of the world is going to overtake us.”
Lefkofsky founded Tempus AI in 2015, soon after his wife was diagnosed with breast cancer. The Chicago-based company has built one of the world’s largest libraries of clinical and molecular data. Tempus AI licenses that data to pharma companies to help them develop clinical trials and match patients with the right cancer drugs. It also has ambitions to expand in other areas, including cardiovascular disease.
Tempus AI shares have risen 68% since the company’s June 2024 initial public offering, giving the company an $11.2 billion market capitalization. It’s one of six companies that Lefkofsky, 57, started that’s been valued at more than $1 billion.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。